New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTGRFS, HALO, CRIS, ING, AMGN, SINA, EXAS, PRAN, MNKD, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
06:08 EDTLULUStocks with implied volatility below IV index mean; LULU HD
Stocks with implied volatility below IV index mean; lululemon (LULU) 31, Home Depot (HD) 16 according to iVolatility.
September 26, 2014
07:45 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
06:09 EDTLULUStocks with implied volatility below IV index mean; LULU HD
Subscribe for More Information
September 25, 2014
08:59 EDTAMGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:11 EDTAMGNAmgen to host conference call
Subscribe for More Information
07:37 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
September 24, 2014
17:01 EDTMNKDMannKind announces closing of global licensing agreement with Sanofi
Subscribe for More Information
07:44 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
07:15 EDTEXASExact Sciences checks show robust early adoption trends, says Jefferies
Jefferies says its analysis of Exact Sciences' enrollment database indicates robust early adoption of Cologuard. The firm has increased conviction in its 2015 test volume forecasts and keeps a Buy rating on the stock with a $20 price target.
06:01 EDTSINASINA implied volatility of 37 at lower end of index mean range
September 23, 2014
15:38 EDTEXASExact Sciences volatility elevated
Subscribe for More Information
September 22, 2014
09:02 EDTAMGNAmgen submits BLA to the FDA for immunotherapy blinatumomab
Subscribe for More Information
September 19, 2014
14:56 EDTEXASExact Sciences volatility elevated
Exact Sciences October call option implied volatility is at 88, November is at 78, January is at 71; compared to its 26-week average of 66 according to Track Data, suggesting large near term price movement.
07:40 EDTLULUVF Corp. upgraded to Buy, could target lululemon, says KeyBanc
As previously reported, KeyBanc upgraded VF Corp (VFC) to Buy from Hold with an $80 price target. The firm cited momentum at its Timberland brand, VF's strong brand portfolio, and the potential for another large M&A transaction. The analyst said VF Corp. is well positioned to complete another large deal and could target lululemon (LULU). KeyBanc believes lululemon's quality issues, forecasting and store operational challenges play into VF Corp.'s strengths and that such an acquisition would be 10c accretive initially and 80c accretive over time.
September 18, 2014
09:05 EDTHALOHalozyme's pancreatic cancer candidate clinical trial approved by FDA to resume
Halozyme announced that the FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial. The trial is designed to evaluate Halozyme's investigational drug PEGPH20 in combination with modified FOLFIRINOX chemotherapy in patients with metastatic pancreatic adenocarcinoma. The study will resume under a revised protocol.
07:52 EDTINGUBS Chair says litigation bigger worry than stress test, Bloomberg reports
Subscribe for More Information
06:39 EDTINGEuropean banks take out EUR83B of loans from central bank, NY Times says
European banks agreed to take out EUR83B in low interest loans from the European Central Bank, as part of a program in which all of the funds must be loaned to businesses or individuals, or repaid to the central bank within two years, according to The New York Times. Several analysts had said that they would be disappointed if banks took out less than EUR100B in loans, but a number of analysts said that a second round of the program, due to occur in December after stress tests have been completed, may be more popular, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
September 17, 2014
11:02 EDTLULUOptions with decreasing implied volatility
Subscribe for More Information
08:03 EDTAMGNAmgen price target raised to $151 from $143 at Morgan Stanley
Morgan Stanley raised Amgen's price target to $151 based on increased brodalumab and AMG 416 expectations. Shares are Overweight rated.
05:51 EDTMNKDStocks with implied volatility movement; OREX MNKD
Stocks with implied volatility movement; Orexigen (OREX) 91, MannKind (MNKD) 60 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use